Tvardi Therapeutics (TVRD) Return on Equity: 2013-2017
Historic Return on Equity for Tvardi Therapeutics (TVRD) over the last 4 years, with Sep 2017 value amounting to -0.63%.
- Tvardi Therapeutics' Return on Equity fell 5.00% to -0.63% in Q3 2017 from the same period last year, while for Sep 2017 it was -0.63%, marking a year-over-year decrease of 5.00%. This contributed to the annual value of -0.74% for FY2016, which is 42.00% down from last year.
- Tvardi Therapeutics' Return on Equity amounted to -0.63% in Q3 2017, which was up 32.59% from -0.94% recorded in Q2 2017.
- Over the past 5 years, Tvardi Therapeutics' Return on Equity peaked at 0.07% during Q4 2013, and registered a low of -1.72% during Q1 2017.
- Over the past 3 years, Tvardi Therapeutics' median Return on Equity value was -0.47% (recorded in 2015), while the average stood at -0.62%.
- As far as peak fluctuations go, Tvardi Therapeutics' Return on Equity skyrocketed by 50bps in 2015, and later crashed by 141bps in 2017.
- Tvardi Therapeutics' Return on Equity (Quarterly) stood at 0.07% in 2013, then plummeted by 41bps to -0.33% in 2014, then grew by 11bps to -0.23% in 2015, then plummeted by 71bps to -0.93% in 2016, then fell by 5bps to -0.63% in 2017.
- Its Return on Equity was -0.63% in Q3 2017, compared to -0.94% in Q2 2017 and -1.72% in Q1 2017.